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oped grade 2 RE, and no one developed grade 3 or more. V5-60 were 
plotted according to grade of RE(ﬁg). V15 (p=0.04), V20 (p=0.03), 
V25 (p=0.03), V30 (p=0.03) and TP (p=0.04) were signiﬁcantly associ-
ated with the development of grade 2 RE.
Conclusions: Esophagus volume received low dose irradiation like 
under V30 and TP might be predictors of RE. 
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Purpose: Retrospective analyses were performed on the patients with 
primary or metastatic lung cancer, who were treated with hypofraction-
ated stereotactic radiation therapy (HSRT).
Patients and Methods: HSRT was applied to 34 patients who were 
unﬁt for either surgery or other systemic therapy since Jan. 1994 till 
Oct. 2006: 14 were with primary lung cancer at cT1~2N0 stages; 20 
were with metastasis. All patients received 5 consecutive daily fractions 
after 3-dimensional conformal planning, and the total doses were 50 
Gy (by 10 Gy/fraction) to 7 patients, and 60 Gy (by 12 Gy/fraction) to 
the remaining 27 patients. The median follow-up period was 13 months 
(range, 2~66 months). Clinical response was evaluated by chest CT in 
one month of HSRT, and the impacts of possible prognostic factors on 
local control and overall survival were evaluated. 
Results: Radiologic complete response was achieved in seven patients 
(20.6%): one in 50 Gy arm (14.3%); six in 60 Gy arm (22.2%). Local 
control and overall survival of all patients at 2 years were 88.4% and 
46.9%. On univariate analyses, tumor size larger than 3 cm was sig-
niﬁcantly adverse factor with respect to local control at 2 years (95.4% 
vs 0%, p=0.02), while lesion nature (primary vs metastatic, p=0.81), 
radiation dose (50 Gy vs 60 Gy, p=0.57), and tumor location (periph-
eral vs central, p=0.28) were not signiﬁcant. No factor had signiﬁcant 
impact on overall survival (Table 1,2). Even though there was one fatal 
acute pneumonitis superimposed on COPD in 60 Gy arm, all acute and 
chronic lung toxicities were grade I or II, and there was no signiﬁcant 
relationship between radiation dose and lung toxicity.
Conclusion: In HSRT for small lung lesion, tumor size was the most 
important factor with respect to local control.
P3-185 NSCLC: Radiation Posters, Wed, Sept 5 – Thurs, Sept 6 
Predicting the risk of symptomatic radiation pneumonitis by 
clinical, dosimetric and biologic parameter in lung cancer patients
Kim, Yeonsil; Kim, Jiyoon; Kim, Young-Kyoun; Park, Hyun-Jin; Kim, 
Suk-Chan; Wang, Young-Pil; Kang, Jin-Hyung; Yoo, Ie-Ryung; Lee, 
Kyu-Young 
Catholic University of Korea, Seoul, Korea
Purpose: Although radiotherapy (RT) improves locoregional control 
and survival in patients with lung cancer, radiation pneumnitis (RP) is 
a common treatment related toxicities. It has been proposed that serial 
measurement of plasma cytokine level can be valuable to estimate risk 
of radiation pneumonitis. Aim of this study was to evaluate the relation 
to the level of serial measurement of plasma cytokines and the develop-
ment of RP and dose volume parameters in 3-D RT plan.
Method and Materials: This prospective study enrolled 30 lung 
cancer patients irradiated with curative intent. Minimum follow-up du-
ration was more than 6 months. Plasma sample obtained before, weekly 
during RT and at 2, 4 weeks follow-up visit after RT. Cytokine analysis 
was performed for IL-1α, IL-6, TNF-αand TGF-β1 using enzyme 
linked immunosorbant assay. All the included patients were treated 
with 3-D conformal RT and dose volume histogram analysis were 
performed. Patients were assessed at each follow-up visit for sign and 
symptoms of RP. RP was determined on the basis of radiologic change 
or symptom of RP scored by RTOG toxicity criteria. We analyzed the 
correlation of symptomatic RP with potential predictive factors (age, 
gender, histology, stage, performance status, underlying lung disease, 
pretreatment pulmonary function test, tumor location, chemotherapy 
or not, chemotherapy regimen or timing, total radiation dose, radiation 
ﬁeld size, fraction size, V20, V30, mean lung dose) and plasma level of 
IL-1α, IL-6, TNF-α and TGF-β1. Univariate and multivariate analyses 
were performed to assess the relationship with RP. 
Results: Overall 8 patients (26.7%) developed RP. Three (10.0%) pa-
tients had grade 3 or higher RP. The multivariate analysis revealed the 
MLD, V20, V30 were the only signiﬁcant factors for symptomatic RP 
occurrence (p<0.05). No associations were found between base line cy-
tokine levels and the risk of RP. IL-6 levels were higher before, during, 
and end of RT in patients with radiation pneumonitis (mean value in RP 
vs non-RP; 35.45 pg/ml vs 15.15 pg/ml, p<0.05) Even though plasma 
level of pre-RT TGF-β1 in RP patients was higher than in non-RP 
patients, it was not statistically signiﬁcant. In patients not developing 
RP, plasma level of TGF-β1 decreased during RT and remained stable 
after RT, however, patients suffering RP had elevated TGF-β1 level 
at the end of RT. These difference of TGF-β1 dynamics between RP 
non-RP patients were marginally signiﬁcant at the end of RT (p=0.06). 
Interestingly, the level of TGF-β1 at the end of RT were associated with 
dosimetric factors such as MLD, V20, V30. Other cytokines, level of 
IL-1α, TNF-α showed stable during whole course of RT and no mean-
ingful changes in association with RP.
Conclusion: The results of our study did not conﬁrm that increase level 
of cytokines are independent signiﬁcant predictive factors for RP pre-
diction in multivariate analysis. Howerver, mean IL-6 level and level 
of TGF-β1 at the end of RT were associated RP occurrence and other 
dosimetric factors.
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Purpose: To evaluate treatment responses, acute toxicities according to 
dose escalation by tomotherapy in non-small cell lung cancer(NSCLC).
Materials and Methods: From May 2006 to January 2007, six patients 
underwent tomotherapy for NSCLC at the Dept. of Radiation Oncol-
ogy, Yonsei Cancer Center. Of the 6 patients, 5 were men and 1 was 
woman. Five patients had adenocarcinoma and 1 had squamous cell 
carcinoma. One patient was stage I, 1 stage IIIA, 4 stage IIIB. To-
motherapy was delivered using Tomotherapy Hi-Art System which 
combines IMRT with a helical delivery pattern to deliver radiation in 
accordance with the prescribed treatment plan. The prescribed dose 
was 75-105 Gy(BED mean 91Gy) to gross tumor volume with 2.5-3 
Gy/fr, 50-55 Gy to clinical target volume with 1.8-2Gy/fr. Induction 
chemotherapy was performed in 5 patients with 3-8 cycles. Concur-
rent chemo-radiotherapy with taxotere or cisplatin was delivered in 5 
patients. 
Results: The response rate after tomotherapy was partial remission in 
5 patients and stable disease in 1. Two patient showed grade II acute 
esophagitis, 1 grade I, 3 grade 0. There was no grade III/IV hemato-
logic toxicity and no symptomatic radiation pneuminitis.
Conclusion: In spite of short clinical experiences, good response rate 
and safe dose escalation without signiﬁcant treatment related acute 
toxicities from sparing of critical normal structures for NSCLC were 
achieved with helical tomotherapy. 
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Purpose: The objective of this study is to evaluate efﬁcacy of helical 
tomotherapy for lung cancer with multiple metastatic lesions
Methods and Materials: Nine non-small cell lung cancer patients 
with multiple metastatic lesions were treated with tomotherapy from 
April 2006 to January 2007. Doses of 50-70 Gy with 2.12-6 Gy/frac-
tion for gross target volume were applied. The V20 (the volume of lung 
irradiated to 20 Gy or above) be kept < 30% to maintain a low risk 
of radiation pneumonitis. Among the patients, 5 patients had separate 
metastatic pulmonary tumor nodules in the ipsilateral or contralateral 
nonprimary tumor lobe of the lung, 4 patients had bone metastasis, 1 
patient had brain metastasis, and 1 patient had adrenal gland metastasis. 
Treatment planning was performed using Tomotherapy Hi-Art System, 
version 2.0 (TomoTherapy, WI, USA), applying simultaneously 
integrated boost technique. Subjective pain response to treatment was 
assessed using the Wisconsin Brief Pain Questionnaire, and the morbid-
ity was evaluated by the Common Terminology Criteria for Adverse 
Events v3.0.
Results: Seven patients received various chemotherapeutic regimens 
before tomotherapy. With regard to pain palliative effect, tomotherapy 
